About Sialic acid-binding Ig-like lectin 6
Sialic acid-binding Ig-like lectin 6 (SIGLEC6) is a protein
from Homo sapiens identified by UniProt accession
O43699, 453 residues long.
MolForge cross-references it against 0 known binders and
115 disease associations.
Target properties
| Protein name | Sialic acid-binding Ig-like lectin 6 |
| UniProt accession | O43699 |
| Gene | SIGLEC6 |
| Organism | Homo sapiens |
| Length | 453 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (115)
Diseases linked to this target (Open Targets).
- sialic acid-binding Ig-like lectin 6 measurement · score 0.34
- blood protein measurement · score 0.32
- protein measurement · score 0.25
- carotid artery intima media thickness · score 0.24
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- chronic lymphocytic leukemia · score 0.10
- MODY · score 0.07
- isolated agammaglobulinemia · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43699-F1 | alphafold | PREDICTED | 77.32 | — |
Amino-acid sequence (453 residues)
MQGAQEASAS EMLPLLLPLL WAGALAQERR FQLEGPESLT VQEGLCVLVP CRLPTTLPAS YYGYGYWFLE GADVPVATND PDEEVQEETR GRFHLLWDPR RKNCSLSIRD ARRRDNAAYF FRLKSKWMKY GYTSSKLSVR VMALTHRPNI SIPGTLESGH PSNLTCSVPW VCEQGTPPIF SWMSAAPTSL GPRTTQSSVL TITPRPQDHS TNLTCQVTFP GAGVTMERTI QLNVSYAPQK VAISIFQGNS AAFKILQNTS SLPVLEGQAL RLLCDADGNP PAHLSWFQGF PALNATPISN TGVLELPQVG SAEEGDFTCR AQHPLGSLQI SLSLFVHWKP EGRAGGVLGA VWGASITTLV FLCVCFIFRV KTRRKKAAQP VQNTDDVNPV MVSGSRGHQH QFQTGIVSDH PAEAGPISED EQELHYAVLH FHKVQPQEPK VTDTEYSEIK IHK
Explore Sialic acid-binding Ig-like lectin 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets